Gainers
- Windtree Therapeutics (NASDAQ:WINT) stock rose 115.4% to $1.2 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.3 million.
- CARISMA Therapeutics (NASDAQ:CARM) stock rose 84.56% to $0.42. The company's market cap stands at $17.4 million.
- Gelteq (NASDAQ:GELS) shares moved upwards by 56.47% to $2.66. The company's market cap stands at $25.1 million.
- Klotho Neurosciences (NASDAQ:KLTO) stock increased by 41.77% to $2.58. The company's market cap stands at $83.8 million.
- Macrogenics (NASDAQ:MGNX) stock rose 23.78% to $2.03. The company's market cap stands at $128.0 million.
- NuCana (NASDAQ:NCNA) shares moved upwards by 21.39% to $0.09.
Losers
- Unicycive Therapeutics (NASDAQ:UNCY) shares fell 48.9% to $0.46 during Tuesday's pre-market session. The company's market cap stands at $55.4 million.
- Citius Pharmaceuticals (NASDAQ:CTXR) stock declined by 24.82% to $1.03. The market value of their outstanding shares is at $10.5 million.
- Liquidia (NASDAQ:LQDA) stock decreased by 16.99% to $14.96. The market value of their outstanding shares is at $1.2 billion.
- Know Labs (AMEX:KNW) stock fell 14.14% to $2.61. The company's market cap stands at $19.5 million.
- United Therapeutics (NASDAQ:UTHR) stock declined by 12.3% to $288.02. The market value of their outstanding shares is at $12.9 billion.
- Citius Oncology (NASDAQ:CTOR) stock declined by 11.39% to $1.09. The market value of their outstanding shares is at $77.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
CTORCitius Oncology Inc
$1.100.92%
CTXRCitius Pharmaceuticals Inc
$1.131.21%
GELSGelteq Ltd
$1.13-0.03%
KLTOKlotho Neurosciences Inc
$0.4496-0.20%
LQDALiquidia Corp
$34.52-1.40%
MGNXMacrogenics Inc
$1.362.26%
NCNANuCana PLC
$4.09-1.16%
UNCYUnicycive Therapeutics Inc
$6.661.22%
UTHRUnited Therapeutics Corp
$479.51-%
WINTWindtree Therapeutics Inc
$0.0603-45.2%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
